Search Results

Beyond Academia: Advising Biotech Carlsson’s collaborative philosophy has also found a place in the biotech It also allows Carlsson to stay plugged into the fast-changing needs of biotech while keeping his academic Biased signaling, allosteric binding sites, and subtype selectivity mean there is rarely a straight line Whether in academia or biotech, the future belongs to research groups that can orchestrate ecosystems And for the next generation of researchers and biotech leaders, that is the real collaboration advantage

Hidden Cost of Good Science Without Systems I’ve seen this pattern again and again—across academia, biotech This is embedded consulting for biotech and VC teams who need to move fast —without compromising scientific Who I Work With ✅ Biotech Teams  – Especially those lacking in-house GPCR leads or overwhelmed by CRO assets in their portfolio. ✅ Contract Research Organizations (CROs)  – Wanting to better align with biotech

GPCR tools and key moves in the biotech world. Dr. Explore this week’s research, tools, and biotech insights in one place.

Corner delivers this week: high-impact insight into GPCR allostery, crafted for pharmacologists and biotech nuance into better decision-making. 🔍 This Week in Premium: Sneak Peek Industry insights:  Strategic biotech This is where funders, peers, and biotech scouts are watching. GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

Ajay Yekkirala shares the journey from academic pharmacologist to biotech entrepreneur—bridging curiosity Learn entrepreneurial lessons rarely shared with postdocs. When the global biotech crowd lands in Boston for Discovery on Target. GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

Discovery programs rarely fail because of one experiment. internalization, calcium flux, ligand binding, and integrated discovery support — systems trusted across pharma, biotech Job Listings  — GPCR-specific career opportunities across academia, biotech, and pharma. Institutional and team memberships receive discounted rates to support coordinated participation.

Meanwhile, the industry is moving fast with AI-powered platforms, bold leadership moves, and strategic biotech Explore this week’s research, tools, and biotech insights in one place.

Watch Episode 168 What does it take for a scientist to become a startup leader in biotech? For Dr. often plague probe development. 👉 Learn more about Celtarys’ science-driven solutions on their company page

In a field like GPCR research (where data complexity and failure rates are high), scientific rigor thrives work at Alkermes didn’t just improve drug screening outcomes, it redefined what great leadership in biotech

GPCR Foundry  — our R&D and biotech hub designed to bridge GPCR science with execution. The Dr. GPCR Foundry: Science Meets Execution The Foundry is where we bring together biotech innovators, Venture , he shares decades of expertise in an accessible, on-demand format for scientists across academia, biotech Anyone who joins Premium before these changes go live will be grandfathered at their current rate , as

In this podcast, he lays out the mindset that helped shape products used across biotech and academia—and Dimensions of Discovery pHSense wasn’t built in a vacuum—it was born from decades of groundwork in rare That opened the door to something rare in functional pharmacology: plate-based GPCR internalization tracking Mini Timeline 🎯 Early 2000s: Trinquet leads IP1 & Tag-lite development 🧪 Mid-2010s: Rare-earth scaffold teaming, testing, and failing smarter. 🚀 Why This Matters: Whether you’re launching a tool, starting a biotech

Discovery at Discovery on Target 2025 — The Track You Can’t Miss If you work in drug discovery  or biotech Over the years, we’ve built a global network of researchers, biotech leaders, and pharma innovators who together. 🚨 Mark your calendar for the GPCR Happy Hour Join us at GPCR Happy Hour , where scientists, biotech

Tools The Story Behind Celtarys – From Chemistry to Company   How does a medicinal chemist become a biotech Explore this week’s research, tools, and biotech insights in one place.

at the GPCR-Targeted Drug Discovery Summit 2026 The meeting brings together 80+ senior leaders from biotech Sessions from InterAx Biotech, Northeastern University, and Function Therapeutics dig into this — moving Companies presenting include Skymab Biotherapeutics, Confo Therapeutics, GSK, Metaphore Biotechnologies

GPCR Premium Membership Gives You an Edge Premium gives GPCR scientists and biotech teams a single, trusted Researchers, pharmacologists, biotech teams, and decision-makers who rely on accurate, efficient, interpretation-first Help us reach more scientists by providing quick rating on Spotify or Apple Podcasts — and a YouTube

Kenakin Trusted insights across biotech, pharma, and academia 💎 $2,999/year — one conference cost = embracing serendipity, Eric shares the mindset (and messy origin stories) that shaped tools now used across biotech GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

Designing for penetration —balance on/off rates to reach inner tissue, not just peripheries. Kenakin Trusted insights from biotech, pharma, and academia 🎬 Plus New: Lesson Trailers   Curious about GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

Dive into this week’s research, tools, and biotech updates all in one place.

need now: a pragmatic framework to interpret kinetic binding experiments and recognize when a drug’s rate Terry Kenakin’s featured talk on “The Kinetics of Allostery” offers a rare live glimpse into advanced insights from major conferences, emerging research, and expert commentary Whether you’re a pharmacologist, biotech GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

. 👉 In biotech, where cycles are long and feedback is slow, this gap becomes even more pronounced. 👉 Founders rarely pause to define decision ownership and escalation paths. Biotech teams operate across disciplines, timelines, and incentives. Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not

Highlights: • The Foundry Arrives : R&D meets biotech with real-world acceleration, strategic consulting GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

Biotech teams, CRO alliances, and academic consortia face the same challenge: how to align incentives This ecosystem design blueprint applies to biotech teams and academic consortia alike.

Explore this week’s research, tools, and biotech insights in one place.

His hybrid path is a model of possibility for professionals in the biotech industry who still dream of

GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need tools, translational strategy, classified updates, and curated jobs—trusted by scientists, teams, and biotech

🔹 Spot the opportunity → Why Catalio is betting big when others pull back Amid biotech slowdowns

Explore this week’s research, tools, and biotech insights in one place.

Did you know that each month we collect the most recent #GPCR publications and the newest Biotech/Pharma

School of Medicine to Receive $3-Million Award from ARPA-H’s Sprint for Women’s Health Nxera Pharma Wins Biotech Year and Financing Deal of the Year at the Citeline Japan Awards 2024 GPCR therapies: Eight promising biotechs

(“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company